New pill shows promise for tough ovarian cancer
NCT ID NCT06084416
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This study tests a new oral drug called sovilnesib in people with advanced high-grade serous ovarian cancer that no longer responds to platinum chemotherapy. The main goal is to find the best dose that is safe and effective. About 120 adults will take the pill daily, and researchers will monitor side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Corewell Health
Grand Rapids, Michigan, 49503, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Georgia Cancer Center Augusta University
Atlanta, Georgia, 30912, United States
-
Hoag Memorial Hospital
Newport Beach, California, 92663, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10128, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
MUSC Hollings Cancer Center
Charleston, South Carolina, 29020, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73117, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
Conditions
Explore the condition pages connected to this study.